Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Holding(s) in Company

9 Jan 2023 15:56

RNS Number : 1409M
Shield Therapeutics PLC
09 January 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYV81293

Issuer Name

SHIELD THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Premier Miton Group plc

City of registered office (if applicable)

GUILDFORD

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Jan-2023

6. Date on which Issuer notified

06-Jan-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.412900

0.000000

5.412900

30000000

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYV81293

30000000

5.412900

Sub Total 8.A

30000000

5.412900%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Premier Miton Group Plc

Premier Asset Management Midco Ltd

Premier Miton Group plc

Premier Asset Management Holdings Ltd

Premier Miton Group plc

Premier Asset Management Limited

Premier Miton Group plc

Premier Investment Group Ltd

Premier Miton Group plc

Premier Fund Managers Ltd

5.412900

5.412900%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

06-Jan-2023

13. Place Of Completion

Guildford, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBLMATMTAMBBJ
Date   Source Headline
29th May 20269:11 amRNSTotal Voting Rights
5th May 20267:00 amRNSGrant of Share Options
1st May 20267:00 amRNSQ1 2026 Trading Update
30th Apr 20267:01 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSEnrollment in Phase II Clinical Trial for ACCRUFeR
9th Apr 202612:30 pmRNSAudited results for year ended 31 December 2025
1st Apr 20269:22 amRNS-RPublication of Report, Reinforcing FDA Approval
31st Mar 20267:03 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSEMA approves extension - to include adolescents
3rd Mar 20267:00 amRNSChinese NMPA Accepts MAA Submission for ACCRUFeR®
27th Feb 20267:00 amRNSTotal Voting Rights
9th Feb 20267:00 amRNSFDA Grants additional Exclusivity for ACCRUFeR
30th Jan 20267:05 amRNSTotal Voting Rights
30th Jan 20267:00 amRNSApproval for ACCRUFeR in China expected in Q1 2026
21st Jan 20267:00 amRNSQ4 2025 Trading Update
2nd Jan 202611:06 amRNSBlock listing 6 Monthly Return
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
18th Dec 20257:13 amRNSBlock Listing Application
11th Dec 20257:00 amRNS-RShield Wins Gold at Titan Branding Awards
3rd Dec 20257:04 amRNSAmends Senior Secured Debt Financing
14th Nov 20257:03 amRNSInitiation of a Phase II Clinical Trial in Japan
11th Nov 20257:00 amRNSACCRUFeR Pediatric PK Results to be Presented
7th Nov 20257:03 amRNSACCRUFeR receives Authorisation by Korean Ministry
23rd Oct 20257:00 amRNSQ3 2025 Trading Update
14th Oct 20253:01 pmRNSGrant of Share Options to Chief Executive Officer
1st Oct 20258:00 amRNSTotal Voting Rights
1st Oct 20257:02 amRNSPositive efficacy and tolerance in pediatric trial
15th Sep 20257:00 amRNS£1.5 million placing supporting growth of ACCRUFeR
4th Sep 20257:03 amRNSACCRUFeR® assigned Priority Review in US by FDA
3rd Sep 20252:17 pmRNSInterim results for the six months ended 30 Jun 25
27th Aug 20257:13 amRNSData published -European Journal of Heart Failure
21st Aug 202512:06 pmRNSInterim results for the six months ended 30 Jun 25
23rd Jul 20257:00 amRNSQ2 2025 Trading Update
22nd May 20255:06 pmRNSResult of AGM
24th Apr 20257:06 amRNSAudited results for the year ended 31 Dec 2024
22nd Apr 20257:01 amRNSLicence Agreement in Japan for ACCRUFeR®
17th Apr 202511:23 amRNSQ1 2025 Trading Update
11th Mar 20257:00 amRNSACCRUFeR® launched in Canada
13th Feb 20254:15 pmRNSPDMR Transaction Notification
13th Feb 20257:00 amRNSGrant of Share Options
5th Feb 20257:00 amRNSUnaudited full year trading update
27th Jan 20257:00 amRNSAnders Lundstrom appointed CEO
24th Dec 202411:25 amRNSResult of General Meeting & Total Voting Rights
23rd Dec 20247:00 amRNSResults of RetailBook Offer
6th Dec 202411:31 amRNSRetailBook Offer
6th Dec 202411:30 amRNSSubscription by AOP Health to raise US$10 million
21st Nov 20247:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.